Arrowhead touts Phase Ib RNAi data for ccRCC; PureTech lines up PD-1 from BeiGene for upcoming combo study
Just days after getting walloped by the news that animal tox data forced them to halt an early-stage cystic fibrosis study, Arrowhead is touting some initial snapshots from their RNAi treatment for clear cell renal cell carcinoma.
Most of the positive signs they’re pointing to relate to biomarker activity, with an average 48% reduction in HIF2α protein among nine evaluable biopsy samples. Those reductions varied widely, though, starting at 9% and growing to 82%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.